28. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in
mice with conditional inactivation of the von Hippel-Lindau tumor
suppressor. Cancer Res. 2006;66(5):2576-2583.
29. Young AP, Kaelin WG, Jr. Senescence triggered by the loss of the
VHL tumor suppressor. Cell Cycle. 2008;7(12):1709-1712.
30. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent
mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature. 2011;469(7331):539-542.
31. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing
of renal carcinoma reveals inactivation of histone modifying genes.
Nature. 2010;463(7279):360-363.
32. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines
a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751-759.
33. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell
renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
34. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon
alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-
124.
35. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon
alfa-2a for treatment of metastatic renal cell carcinoma: a randomised,
double-blind phase III trial. Lancet. 2007;370(9605): 2103-
2111.
36. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon
alfa compared with interferon alfa monotherapy in patients with
metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;
26(33):5422-5428.
37. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of
axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a
randomised phase 3 trial. Lancet. 2012;378(9807):1931-1939.
38. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus
everolimus in advanced renal cell carcinoma (METEOR): final results
from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7):
917-927.
39. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in
metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
40. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced
or metastatic renal cell carcinoma: results of a randomized
phase III trial. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2010;28(6):1061-1068.
41. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and
the combination in patients with metastatic renal cell carcinoma: a
randomised, phase 2, open-label, multicentre trial. Lancet Oncol.
2015;16(15):1473-1482.
42. Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib
therapy in patients with von Hippel-Lindau disease. Ann Oncol.
2011;22(12):2661-2666.
43. Jonasch E, McCutcheon IE, Gombos DS, et al. Pazopanib in patients
with von Hippel-Lindau disease: a single-arm, single-centre, phase 2
trial. Lancet Oncol. 2018;19(10):1351-1359.
44. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia
inducible factor is sufficient for growth suppression of VHL-/-
tumors. Mol Cancer Res. 2004;2(2):89-95.
45. Wallace EM, Rizzi JP, Han G, et al. A Small-Molecule Antagonist of
HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Cancer Res. 2016;76(18):5491-5500.
46. Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma
with a HIF-2 antagonist. Nature. 2016;539(7627):112-117.
47. Courtney KD, Infante JR, Lam ET, et al. Phase I Dose-Escalation
Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2alpha Antagonist
in Patients With Previously Treated Advanced Clear Cell Renal
Cell Carcinoma. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2018;36(9):867-874.
48. Jonasch E, Klaassen Z. A First-in-Human Phase 1/2 Trial of the Oral
HIF-2a Inhibitor PT2977 in Patients with Advanced RCC (Clinical trial
identification: NCT02974738). ESMO 2019; 2019; Barcelona, Spain.
49. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med.
2019;380(12):1103-1115.
50. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med.
2019;380(12):1116-1127.
51. Liu XD, Hoang A, Zhou L, et al. Resistance to Antiangiogenic Therapy
Is Associated with an Immunosuppressive Tumor Microenvironment
in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015;
3(9):1017-1029. KCJ
/kidneycancer.org